Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Developmentally regulated endothelial locus 1 (DEL-1), also known as EGF-like repeats and discoidin I-like domains 3 (EDIL3), is a secreted glycoprotein primarily produced by endothelial cells and certain macrophage subsets. It plays critical roles in vascular biology, immune regulation, inflammation resolution, and tissue remodeling. DEL-1 interacts with several integrins via its RGD motif or other structural features, modulating cell adhesion, angiogenesis, inflammation, and bone formation. It is considered a promising therapeutic target for chronic inflammatory diseases, cardiovascular/metabolic disorders, ischemic injury recovery strategies, and autoimmune conditions.
DEL-1 interacts with integrins (αvβ3, αvβ5, αLβ2, αMβ2) and other molecules to modulate cell adhesion, migration, angiogenesis, immune cell recruitment, and efferocytosis, impacting inflammatory and vascular processes. It also affects osteogenic differentiation via integrin signaling.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Developmentally Regulated Endothelial Locus 1 (DEL-1).